Skip to content

Evaluation of preoperative staging and treatment response of rectal cancer after neoadjuvant chemoradiation by three-dimensional transrectal ultrasound——a multi-center prospective clinical study in China

Evaluation of preoperative staging and treatment response of rectal cancer after neoadjuvant chemoradiation by three-dimensional transrectal ultrasound——a multi-center prospective clinical study in China

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023969
Enrollment
Unknown
Registered
2019-06-20
Start date
2019-09-25
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Interventions

Gold Standard:pathology ,MRI
ultrasound

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Biopsy-proven primary rectal adenocarcinoma; 2)Initial patients without any treatment; 3)Pathology can be obtained by operation in our hospital. 4)All patients were examined by transrectal 3D ultrasound before treatment, and the upper edge of the lesion could be completely detected by ultrasound probe (it is suggested that the tumors should be located within 10 cm from the anus). The image data were complete. 5)Patients should understand and be willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Incomplete or inferior image data of three-dimensional transrectal ultrasound pre- and post-neoadjuvant therapy. 2) Combined with severe chronic cardiovascular and cerebrovascular diseases, liver and gallbladder, kidney diseases, and other malignant tumors or immunodeficiency diseases; existing or combined with hemorrhagic diseases; pregnant or lactating women and other uncontrollable and inoperable patients.

Design outcomes

Primary

MeasureTime frame
staging;SEN, SPE, ACC, PPV, NPV, Kappa;

Secondary

MeasureTime frame
pathologic complete response;

Countries

China

Contacts

Public ContactLi Anhua

Department of Ultrasound, Sun Yat-Sen University Cancer Center

liah@sysucc.org.cn+86 020 87343211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026